14 completed, 4 active not recruiting, 3 unknown, 2 recruiting. 27 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Completed 14, Active not recruiting 4, Unknown 3, Recruiting 2, Terminated 2, Withdrawn 2 |
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Hepatitis D: new trials by email Literature Review of Hepatitis D trials Research Report on Hepatitis D
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Brelovitug (BJT-778), Bulevirtide - Chronic Hepatitis D | Phase 2 / Phase 3 | Recruiting | Mirum Pharmaceuticals, Inc. | 120 | 2026-02-26 | 2026-10-27 |
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis | Phase 2 | Active not recruiting | Vir Biotechnology, Inc. | 100 | 2025-08-05 | 2026-01-16 |
| Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus GS-4321, GS-4321 Placebo - Chronic Hepatitis Delta | Phase 1 / Phase 2 | Recruiting | Gilead Sciences | 200 | 2025-07-31 | 2026-08-27 |
| A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg - Chronic Hepatitis D Infection | Phase 2 / Phase 3 | Active not recruiting | Mirum Pharmaceuticals, Inc. | 150 | 2025-03-25 | 2026-10-27 |
| A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D hepalatide - Hepatitis D | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 90 | 2024-12-11 | 2026-10-29 |
| Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis D RBD1016, Placebo - Chronic Hepatitis D | Phase 2 | Active not recruiting | Ribocure Pharmaceuticals AB | 14 | 2024-08-21 | 2026-10-15 |
| Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis Peginterferon Lambda - Chronic Hepatitis Delta | Phase 2 | Withdrawn | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2024-05-22 | 2024-05-23 | |
| Study of Hepalatide in Chronic Hepatitis D(CHD) Patients Hepalatide, Hepalatide Placebo - Chronic Hepatitis D Infection | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 23 | 2023-10-07 | 2024-04-24 |
| A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection Ursodeoxycholic acid, Ropeginterferon alfa-2b, Tenofovir Alafenamide - Hepatitis D | Phase 2 | Unknown | National Taiwan University Hospital | 30 | 2023-02-24 | 2022-12-29 |
| SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. VIR-2218, VIR-3434, NRTI - Hepatitis D, Chronic | Phase 2 | Active not recruiting | Vir Biotechnology, Inc. | 95 | 2022-09-17 | 2026-06-26 |
| A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection ATI-2173, Viread, AB-729 - Hepatitis B, Chronic, Hepatitis D | Phase 2 | Terminated | Antios Therapeutics, Inc | 40 | 2021-03-30 | 2022-11-18 |
| A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus JNJ-73763989, Placebo, Entecavir (ETV) monohydrate - Hepatitis D, Chronic | Phase 2 | Completed | Janssen Research & Development, LLC | 52 | 2020-09-17 | 2026-07-22 |
| Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa) - Chronic Hepatitis Delta | Phase 2 | Completed | Gilead Sciences | 175 | 2019-05-31 | 2024-10-08 |
| Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon Peg-interferon lambda, Lonafarnib, Ritonavir - Liver Disease, Hepatitis D | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 26 | 2018-08-01 | 2021-12-14 |
| Ezetimibe for Patients With Chronic Hepatitis D Ezetimibe - Chronic Hepatitis D | Phase 2 | Unknown | Ziauddin Hospital | 20 | 2017-01-01 | 2017-04-04 |
| A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection Peginterferon Lambda-1A - Hepatitis D, Chronic | Phase 2 | Completed | EIT Pharma, Inc. | 33 | 2016-10-19 | 2026-09-08 |
| A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D Myrcludex B, Myrcludex-B, Tenofovir - Chronic Hepatitis D Infection With Hepatitis B | Phase 2 | Completed | Hepatera Ltd. | 120 | 2016-02-16 | 2021-05-10 |
| Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D Pegylated interferon alfa, Ezetimibe - Hepatitis D, Chronic | Phase 2 | Unknown | Aga Khan University | 20 | 2016-01-01 | 2017-04-07 |
| Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) ARC-520, entecavir, pegylated interferon alpha 2a - Hepatitis B, Hepatitis D | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 79 | 2015-12-01 | 2026-01-13 |
| Titrating-Dose of Lonafarnib in Combination With Ritonavir lonafarnib, Ritonavir - Chronic Delta Hepatitis | Phase 2 | Completed | EIT Pharma, Inc. | 15 | 2015-09-01 | 2026-09-25 |
Showing 20 of 27. Sign in to see all of them.
Hepatitis D, Chronic (16) · Hepatitis (4) · Fibrosis (3) · Liver Diseases (3) · Hepatitis B, Chronic (2) · Hepatitis, Chronic (2) · Digestive System Diseases (1) · Glomerulonephritis (1) · Hepatitis B (1) · Polyarteritis Nodosa (1)
Hepatitis, Viral, Human (27) · Infections (27) · RNA Virus Infections (27) · Virus Diseases (27) · Digestive System Diseases (26) · Liver Diseases (24) · Hepatitis (23) · Pathologic Processes (20) · Pathological Conditions, Signs and Symptoms (20) · Chronic Disease (19) · Disease Attributes (19) · Hepatitis, Chronic (17) · Blood-Borne Infections (3) · Communicable Diseases (3)
Tenofovir (5) · lonafarnib (5) · Ritonavir (4) · peginterferon alfa-2a (4) · bulevirtide (3) · Ezetimibe (2) · entecavir (2) · myrcludex-B (2) · peginterferon lambda-1a (2) · tenofovir alafenamide (2) · ARC-520 (1) · Histamine Antagonists (1) · Lamivudine (1) · Ribavirin (1) · Treatment Delay (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (6) · EIT Pharma, Inc. (2) · Gilead Sciences (2) · Mirum Pharmaceuticals, Inc. (2) · Shanghai HEP Pharmaceutical Co., Ltd. (2) · Vir Biotechnology, Inc. (2) · Aga Khan University (1) · Antios Therapeutics, Inc (1) · Arrowhead Pharmaceuticals (1) · Eiger BioPharmaceuticals (1) · HepNet Study House, German Liverfoundation (1) · Hepatera Ltd. (1) · Hoffmann-La Roche (1) · Janssen Research & Development, LLC (1) · National Taiwan University Hospital (1)
United States (9) · Germany (7) · Moldova (7) · Romania (6) · Bulgaria (5) · France (5) · Italy (5) · New Zealand (5) · Pakistan (4) · Taiwan (4) · United Kingdom (4) · Australia (3) · China (3) · Russia (3) · Spain (3)
Theo Heller, M.D. (3) · Christopher Koh, M.D. (2) · David Apelian, MD, PhD, MBA (1) · Eduardo B Martins, MD, DPhil (1) · Heiner Wedemeyer, MD, PhD (1) · Heiner Wedemeyer, MD,PhD (1) · Junqi Niu (1) · Michael P. Manns, Prof. Dr. (1) · Oyunbileg Janchiv (1) · Pei-Jer Chen (1)
PMID 30664876, PMID 41586499, PMID 26189433, PMID 30516520, PMID 30833068, PMID 34048594, PMID 36113537, PMID 37120031, PMID 37787009, PMID 38340811, PMID 38842520, PMID 39648559, PMID 40087915, PMID 41211943, PMID 41317314
2015 (1), 2019 (1), 2023 (1), 2025 (1)